The coronavirus crisis spurred a tremendous wave of innovation and collaboration in life sciences, and nowhere more so than in the United States. But will renewed public trust in the pharma industry endure beyond the pandemic? How are product pipelines evolving? What are the prospects for US healthcare reform?
The US Pharma and Biotech Summit returned for two days of live panel discussions and keynote interviews with senior industry executives, investors and thought leaders. Sessions explored the latest trends in areas like drug development, market access, supply chains and health policy.
Leading and learning
Renewed public trust in the industry, the legacy of collaboration during the pandemic and priorities for investment
Innovating and enabling
New applications for advanced therapies, the future of clinical trials and the impact of digital transformation on workforces
Scaling up and ensuring access
The evolution of supply chain management, prospects for US healthcare reform and the potential impact on market access
World-class speakers include
Biogen U.S. Organization
Chairman and CEO
Chairman of the Board and Chief Executive Officer
Bristol Myers Squibb
Kite, a Gilead Company
Chief Scientific Officer & President
US Breaking News Editor
US Lex Editor
Global Pharmaceuticals Correspondent
Global Health Editor
"FT US Pharma and Biotech Summit is a must attend event, even in its virtual format presently required, since all of the leading companies and industry consultants send their top executives to speak on the future of our industry and they address both the difficult and the inspirational aspects of rapidly advancing technologies to deliver future healthcare innovation." Executive Chairman, KOP Therapeutics Corp
FT Live 2020: The Year in Review
We would like to take this opportunity to look back and reflect on some incredible moments from last year. Thank you for being a part of the FTLive community and for your continued support.